PaysignPAYS
PAYS
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
457% more call options, than puts
Call options by funds: $245K | Put options by funds: $44K
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
37% more capital invested
Capital invested by funds: $42.2M [Q3] → $57.7M (+$15.5M) [Q4]
14.04% more ownership
Funds ownership: 21.65% [Q3] → 35.7% (+14.04%) [Q4]
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
0% more funds holding
Funds holding: 90 [Q3] → 90 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
135%
upside
Avg. target
$5.50
158%
upside
High target
$6
182%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Barrington Research Gary Prestopino 39% 1-year accuracy 61 / 157 met price target | 135%upside $5 | Outperform Maintained | 27 Mar 2025 |
DA Davidson Peter Heckmann 51% 1-year accuracy 24 / 47 met price target | 182%upside $6 | Buy Maintained | 26 Mar 2025 |
Financial journalist opinion
Based on 3 articles about PAYS published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Paysign, Inc. (PAYS) Q4 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Matt Lanford - CPO Conference Call Participants Jacob Stephan - Lake Street Capital Markets Gary Prestopino - Barrington Research Peter Heckmann - D.A. Davidson Operator Good afternoon.

Neutral
Business Wire
6 days ago
Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results.

Neutral
Business Wire
1 week ago
Paysign, Inc. Announces Acquisition of Gamma Innovation's Assets, Appoints Michael Ngo as Chief Innovation Officer
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as.

Neutral
Business Wire
1 month ago
Paysign to Host Fourth Quarter and Full Year 2024 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Fourth Quarter and Full Year 2024 Earnings Call.

Positive
Seeking Alpha
1 month ago
Paysign: Shifting Revenue Mix, Falling Stock, Compelling Opportunity
Paysign, Inc. is a small healthcare-focused Fintech company excelling in the $500M Patient Affordability market, with 230% revenue growth in its Pharma segment over the past four quarters. Despite a 40% stock decline in six months, Paysign's strong fundamentals and innovative solutions present a compelling investment opportunity with a fair value estimate of $3.33 per share. Paysign's strategic focus on Plasma and Patient Affordability programs, vertical integration, and innovation has driven significant growth and improved margins, funded entirely through organic cash flow.

Neutral
Business Wire
1 month ago
Paysign Announces 2024 Performance Analysis of Patient Affordability Solutions
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign Announces 2024 Performance Analysis of Patient Affordability Solutions.

Positive
Seeking Alpha
4 months ago
Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion.

Neutral
Seeking Alpha
4 months ago
Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Mark Newcomer - President and CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Conference Call Participants Pete Heckmann - D.A. Davidson Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Thalmann Operator Good afternoon.

Neutral
Business Wire
4 months ago
Paysign, Inc. Reports Third Quarter 2024 Financial Results
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial results for the third quarter 2024. “We are pleased to report strong third-quarter results, achieving 23.0% revenue growth and a 20.6% increase in adjusted EBITDA,” said Mark Newcomer, President & CEO of Paysign. “Revenue from patient affordability prog.

Neutral
Business Wire
5 months ago
Paysign to Host Third Quarter 2024 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Third Quarter 2024 Earnings Call.

Charts implemented using Lightweight Charts™